[go: up one dir, main page]

DK1530724T3 - Diagnose og forebyggelse af cancercelleinvasion - Google Patents

Diagnose og forebyggelse af cancercelleinvasion

Info

Publication number
DK1530724T3
DK1530724T3 DK03763885.5T DK03763885T DK1530724T3 DK 1530724 T3 DK1530724 T3 DK 1530724T3 DK 03763885 T DK03763885 T DK 03763885T DK 1530724 T3 DK1530724 T3 DK 1530724T3
Authority
DK
Denmark
Prior art keywords
prevention
cancer cell
cell invasion
diagnosis
malignant disorders
Prior art date
Application number
DK03763885.5T
Other languages
English (en)
Inventor
Pjotr Knyazev
Tatjana Knyazeva
Axel Ullrich
Yuri Cheburkin
Peter Vajkoczy
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK1530724T3 publication Critical patent/DK1530724T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK03763885.5T 2002-07-17 2003-07-17 Diagnose og forebyggelse af cancercelleinvasion DK1530724T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02015944A EP1382969A1 (en) 2002-07-17 2002-07-17 Diagnosis and prevention of cancer cell invasion
PCT/EP2003/007786 WO2004008147A2 (en) 2002-07-17 2003-07-17 Diagnosis and prevention of cancer cell invasion

Publications (1)

Publication Number Publication Date
DK1530724T3 true DK1530724T3 (da) 2010-08-02

Family

ID=29762643

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03763885.5T DK1530724T3 (da) 2002-07-17 2003-07-17 Diagnose og forebyggelse af cancercelleinvasion

Country Status (11)

Country Link
US (2) US8277802B2 (da)
EP (4) EP1382969A1 (da)
JP (2) JP5419316B2 (da)
CN (2) CN1739030A (da)
AT (1) ATE462973T1 (da)
AU (2) AU2003250984B2 (da)
CA (1) CA2493111C (da)
DE (1) DE60331921D1 (da)
DK (1) DK1530724T3 (da)
ES (1) ES2343950T3 (da)
WO (1) WO2004008147A2 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60021068T2 (de) 1999-04-09 2006-05-18 Rigshospitalet Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
US8574827B2 (en) 2002-10-29 2013-11-05 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
JP4942219B2 (ja) * 2005-04-07 2012-05-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および処置におけるｄｄｒ２
DK2006381T3 (da) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd Fremgangsmåde til regulering af antistoffers blodfarmakokinetik
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
WO2008127707A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
CA2692320A1 (en) * 2007-07-02 2009-01-08 Wyeth Methods of treating bone disorders with modulators of axl
DK2202245T3 (da) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd Fremgangsmåde til modificering af et antistofs isoelektriske punkt via aminosyresubstitution i cdr
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
WO2009054939A2 (en) * 2007-10-19 2009-04-30 Cell Signaling Technology, Inc. Cancer classification and methods of use
EP2220121B1 (en) * 2007-11-12 2015-08-19 U3 Pharma GmbH Axl antibodies
BRPI0820543A2 (pt) * 2007-11-15 2015-06-16 Chugai Pharmaceutical Co Ltd Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
US20120230991A1 (en) * 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
JP2013520958A (ja) * 2009-03-13 2013-06-10 ベルゲン テクノロジオヴェルフォリング エイエス 上皮間葉転換のバイオマーカーとしてａｘｌを使用する方法
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
KR20120035145A (ko) * 2009-05-11 2012-04-13 우드라이 파마 게엠베하 인간화 ａｘｌ 항체
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
MX2011012136A (es) * 2009-05-15 2012-04-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl.
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
RU2556822C2 (ru) * 2010-01-22 2015-07-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Ингибирование axl сигнализации в антиметастатической терапии
WO2011159980A1 (en) 2010-06-18 2011-12-22 Genentech, Inc. Anti-axl antibodies and methods of use
AU2011291450B2 (en) 2010-08-19 2015-05-14 Howard Florey Institute TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
WO2012096933A1 (en) * 2011-01-10 2012-07-19 Trustees Of Dartmouth College Methods for screening for drug resistance in cancer treatment
WO2012175691A1 (en) * 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
AU2012273955A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
US9499856B2 (en) 2012-04-02 2016-11-22 The Board Institute, Inc. DDR2 mutations in squamous cell lung cancer
FI2931265T6 (fi) 2012-12-14 2023-05-23 Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6195716B2 (ja) * 2013-02-15 2017-09-13 富士レビオ株式会社 抗癌剤耐性診断マーカー
JP6567973B2 (ja) 2013-11-27 2019-08-28 株式会社カネカ 細胞培養培地及びそれを用いた培養方法
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
JP6679489B2 (ja) * 2014-01-03 2020-04-15 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病についての有効な末梢診断法に対する凝集率の収束
EP3186284B1 (en) 2014-08-28 2022-04-06 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
JP2017205021A (ja) * 2014-09-26 2017-11-24 Jsr株式会社 初代癌細胞のスフェロイド作製方法、スフェロイド、スクリーニング方法、及び、診断方法
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
JP6931609B2 (ja) 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
WO2017180842A1 (en) 2016-04-15 2017-10-19 Bioatla, Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
JP7051715B2 (ja) 2016-05-13 2022-04-11 バイオアトラ、エルエルシー 抗Ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
US12187801B2 (en) 2017-01-18 2025-01-07 Exuma Biotech Corp. Chimeric antigen receptors against AXL or ROR2 and methods of use thereof
KR102357045B1 (ko) 2017-03-31 2022-01-28 뉴로디아그노스틱스 엘엘씨 알츠하이머 질환에 대한 림프구-기반 형태계측 시험
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
JP7029745B2 (ja) * 2017-12-05 2022-03-04 国立大学法人金沢大学 膠芽腫マーカー及びその使用
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
JP2023521753A (ja) 2020-04-08 2023-05-25 ベルゲンビオ アーエスアー 抗ウイルス療法
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE4110405A1 (de) * 1991-03-28 1992-10-01 Birchmeier Walter Prof Dr Verfahren zum nachweis der differenzierung und der invasivitaet von karzinomzellen
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
AU729247B2 (en) 1996-08-12 2001-01-25 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
AU5077100A (en) * 1999-06-10 2001-01-02 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Non-human transgenic animals deficient in gas6 function and their use
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU1339701A (en) * 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
EP1240322A2 (en) * 1999-12-23 2002-09-18 Exiqon A/S Therapeutic uses of lna-modified oligonucleotides
WO2001078778A1 (en) * 2000-04-13 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie (Vib) USE OF INHIBITION OF A Gas6 FUNCTION OR OF A Gas6 RECEPTOR FOR PREVENTING AND TREATING A CARDIOVASCULAR DISEASE
EP1353947A2 (en) 2000-12-08 2003-10-22 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법

Also Published As

Publication number Publication date
WO2004008147A2 (en) 2004-01-22
EP1530724A2 (en) 2005-05-18
AU2003250984A1 (en) 2004-02-02
ATE462973T1 (de) 2010-04-15
AU2009251103B2 (en) 2013-09-05
CA2493111C (en) 2016-07-05
JP2005532805A (ja) 2005-11-04
EP2267454A2 (en) 2010-12-29
JP2011024580A (ja) 2011-02-10
AU2003250984B2 (en) 2009-10-08
CA2493111A1 (en) 2004-01-22
WO2004008147A3 (en) 2004-05-27
CN1739030A (zh) 2006-02-22
EP1382969A1 (en) 2004-01-21
US8277802B2 (en) 2012-10-02
US20130084300A1 (en) 2013-04-04
EP2228654A2 (en) 2010-09-15
AU2009251103A1 (en) 2010-01-21
EP1530724B1 (en) 2010-03-31
JP5419316B2 (ja) 2014-02-19
ES2343950T3 (es) 2010-08-13
CN102349997A (zh) 2012-02-15
EP2228654A3 (en) 2011-01-05
US20050186571A1 (en) 2005-08-25
EP2267454A3 (en) 2011-03-30
DE60331921D1 (de) 2010-05-12

Similar Documents

Publication Publication Date Title
DK1530724T3 (da) Diagnose og forebyggelse af cancercelleinvasion
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
TNSN05300A1 (en) Treatment with anti-vegf antibodies
NO20043246L (no) Nye fremgangsmater til diagnose og behandling av tumorer
EP1578380A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
DK1587837T3 (da) Epitopsekvenser til diagnose og behandling af prostatacancer
ATE491385T1 (de) Schutzhülle für ein medizinprodukt und herstellungsverfahren dafür
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20071791L (no) Preparater og fremgangsmater for diagnostiseringen og behandlingen av tumor
PL374865A1 (en) Treatment of tnf alpha related disorders
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
IS8071A (is) Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
EP1575571A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
NO20054744L (no) Behandling av Alzheimers sykdom
WO2005030266A3 (en) Optical imaging of colorectal cancer
NO20053903D0 (no) Nukleotidlipidesterderivater.
TR200601622A2 (tr) Otomatik Üst Çene Genişleticisi
WO2006094068A3 (en) Hdac inhibitors that promote brm expression and brm related diagnostics
DK1359943T3 (da) Biotinderivater og deres konjugater med chelateringsmidler
AU2003272189A8 (en) Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
WO2004005540A3 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen
ITBO20030261A1 (it) Unita'di irraggiamento luminoso per diagnosi e cura di problemi cutanei.
NO20055449D0 (no) Fremgangsmate for diagnostisering av behandling av kreft